Xoma Royalty将收购Generation Bio

2025-12-16 06:28

XOMA Royalty (XOMA) has entered into an agreement to acquire Generation Bio (GBIO) for a cash price of $4.2913 per share.
Generation Bio stockholders also will receive one non-transferable contingent value right (“CVR”) per share that entitles holders to receive potential payments of a pro rata portion of:
- 100% of the amount by which net cash at closing, as finally determined pursuant to the CVR agreement, exceeds $29 million;
- either 90% or 100% of any savings realized by XOMA Royalty on the Company’s Cambridge office lease obligations, subject to the timing of resolution of the lease obligations;
- a share of any proceeds from Generation Bio’s existing license agreement with Moderna, which includes potential development and commercial milestones and royalties on commercial sales, calculated on a sliding scale delivering up to 90% of such payments to CVR holders; and
- a share of payments from any out license or sale of the Generation Bio ctLNP delivery platform, calculated on a sliding scale delivering up to 70% of such payments to CVR holders following the closing.
XOMA -1.14% after hours to $25.2.
Source: Press Release

More on XOMA, Generation Bio